Is It Influenza or Anthrax? A Decision Analytic Approach to the Treatment of Patients with Influenza-like Illnesses

Annals of Emergency Medicine

Volumn 43, Issue 3, 2004, Pages 318-328

  Fine, Andrew M ^a   Wong, John B ^b   Fraser, Hamish S F ^a   Fleisher, Gary R ^a   Mandl, Kenneth D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN;

ADVERSE DRUG REACTION; ANALYTIC METHOD; ANTHRAX; ARTICLE; BLOOD CULTURE; CALCULATION; DECISION MAKING; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EMERGENCY WARD; FEVER; FLU LIKE SYNDROME; HUMAN; INFLUENZA; MORBIDITY; PRIORITY JOURNAL; PROBABILITY; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY;

EID: 1442311691     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2003.09.007     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention. Notice to readers: evaluation of post-exposure antibiotic prophylaxis to prevent anthrax. MMWR Morb Mortal Wkly Rep. 2002;51:59.
2. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis. 2002;8:1124-1132.
3. Centers for Disease Control and Prevention. Notice to readers: considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:984-986.
4. Kuehnert MJ, Doyle TJ, Hill HA, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis. 2003;36:328-336.
5. Inglesby T, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287:2236-2252.
6. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:941-948.
7. Swartz MN. Recognition and management of anthrax: an update. N Engl J Med. 2001;345:1621-1626.
8. Shafazand S, Doyle R, Ruoss S, et al. Inhalational anthrax: epidemiology, diagnosis, and management. Chest 1999;116:1369-1376.
9. Mayer TA, Bersoff-Matcha S, Murphy C, et al. Clinical presentation of inhalational anthrax following bioterrorism exposure. JAMA. 2001;286:2549-2553.
10. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management: Working Group on Civilian Biodefense [erratum appears in JAMA. 2000;283:1963]. JAMA. 1999;281:1735-1745.
11. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management: Working Group on Civilian Biodefense [erratum appears in JAMA. 2000;283:1963]. JAMA. 1999;281:1735-1745.
12. Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J of Med. 1999;341:815-826.
13. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266:1202-1208.
14. Williams JL, Noviello SS, Griffith KS, et al. Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001. Emerg Infect Dis. 2002;8:1133-1137.
15. Jefferds MD, Laserson K, Fry AM, et al. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, DC, 2001. Emerg Infect Dis. 2002;8:1138-1144.
16. Henretig FM, Cieslak TJ, Kortepeter MG, et al. Medical management of the suspected victim of bioterrorism: an algorithmic approach to the undifferentiated patient. Emerg Med Clin North Am. 2002;20:351-364.
17. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001;7:933-944.
18. Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002;8:222-225.
19. Stolberg SG. For anthrax survivors, a halting painful recovery. New York Times. May 7, 2002;Section F:1.
20. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160:3243-3247.
21. Covalciuc K, Webb K, Carlson C. Comparison of four clinical specimen types for detection of influenza A and B viruses by optical immunoassay (FLU OIA Test) and cell culture methods. J Clin Microbiol. 1999;37:3971-3974.
22. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis. 2003;22:164-177.
23. National Center for Health Statistics. Fast Stats: Influenza. Available at: http:// www.cdc.gov/nchs/fastats/flu.htm. Accessed April 25, 2003.
24. Williams AA, Parashar UD, Stoica A, et al. Bioterrorism-related anthrax surveillance, Connecticut, September-December, 2001. Emerg Infect Dis. 2002;8:1078-1082.
25. Medical Economics Staff. Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics Company; 2002.
26. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Mortal Wkly Rep. 2001;50:973-976.
27. Dietz BL. The fluoroquinolones. Clin Toxicol Rev. 1997;20:1-2.
28. Centers for Disease Control and Prevention. Update: adverse events associated with anthrax prophylaxis among postal employees: New Jersey, New York City, and the District of Columbia Metropolitan Area, 2001. MMWR Morb Mortal Wkly Rep. 2001;50:1051-1054.
29. Segev S, Yaniv I, Haverstock O, et al. Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. Clin Infect Dis. 1999;28:299-308.
30. Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med. 1989;111:1041-1043.
31. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001;161:15-21.
32. Yocum MW, Butterfield JH, Klein JS, et al. Epidemiology of anaphylaxis in Olmsted County: a population-based study. J Allergy Clin Immunol. 1999;104(2 pt 1):452-456.
33. Kaplan RM, Bush JW, Berry CC. Health status index: category rating versus magnitude estimation for measuring levels of well-being. Med Care. 1979;17:501-525.
34. Hupert N, Bearman GML, Mushlin AI, et al. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med. 2003;139(5 part 1):337-345.
35. Sox HC. A triage algorithm for inhalational anthrax. Ann Intern Med. 2003;139(5 part 1):379-381.
36. Sackett D, Haynes R, Tugwell P, et al. Clinical Epidemiology: A Basic Science for Clinical Medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1991.
37. Schapira MM, Matchar DB, Young MJ. The effectiveness of ovarian cancer screening: a decision analysis model. Ann Intern Med. 1993;118:838-843.
38. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions: standardizing data on outcomes. N Engl J Med. 1998;339:380-386.
39. Wein LM, Craft DL, Kaplan EH. Emergency response to an anthrax attack. Proc Natl Acad Sci USA. 2003;100:4346-4351.
40. Sacchi CT, Whitney AM, Mayer LW, et al. Sequencing of 16S rRNA gene: a rapid tool for identification of Bacillus anthracis. Emerg Infect Dis. 2002;8:1117-1123.
41. Quinn CP, Semenova VA, Elie CM, et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis. 2002;8:1103-1110.
42. De BK, Bragg SL, Sanden GN, et al. A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthracis. Emerg Infect Dis. 2002;8:1060-1065.
43. Lober WB, Karras BT, Wagner MM, et al. Roundtable on bioterrorism detection: information system-based surveillance. J Am Med Inform Assoc. 2002;9:105-115.